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Background
The anti-diabetic drug metformin has been shown to
affect cancer cell metabolism [1,2] and to display anti-
tumoral properties in numerous cancers [3,4], however, its
role in the formation of metastases remains poorly docu-
mented. Cell migration is a critical step in the progression
of prostate cancer to the metastatic state, the lethal form
of the disease.
Results
We show here that metformin reduces the occurrence of
metastases in an orthotopic metastatic prostate cancer cell
model established in nude mice. As predicted, metformin
hampers cell motility in PC3 and DU145 prostate cancer
cells and triggers a radical reorganization of the cell cytos-
keleton. The small GTPase Rac1 is a master regulator of
cytoskeleton organization and cell migration. We report
that metformin inhibits Rac1 GTPase activity by interfer-
ing with some of its multiple upstream signaling pathways,
namely P-Rex1 (a Guanine nucleotide exchange factor and
activator of Rac1), cyclic AMP and CXCL12/CXCR4,
resulting in decreased migration of prostate cancer cells.
Importantly, overexpression of a constitutively active form
of Rac1 (Rac1-Q61L or Rac1-V12), or P-Rex1 as well as
the inhibition of the adenylate cyclase were able to reverse
the anti-migratory effects of metformin.
Conclusion
Our results establish a novel mechanism of action for
metformin through Rac1 and highlight its potential anti-
metastatic properties in prostate cancer.
Acknowledgement
This research was supported by The French National Institute for Cancer
(INCa) and The foundation ARC.
Authors’ details
1INSERM U1065, C3M, Nice, France. 2CNRS U5089, IPBS, Toulouse, France.
3Rangeuil Hospital, Toulouse, France.
Published: 28 May 2014
References
1. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X:
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted
on the respiratory chain complex I. J Biol Chem 2000, 275:223-8.
2. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al:
Targeting cancer cell metabolism: the combination of metformin and 2-
deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.
Cancer Res 2010, 70:2465-75.
3. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P,
et al: The antidiabetic drug metformin exerts an antitumoral effect in
vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008,
27:3576-86.
4. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an
AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer
Res 2006, 66:10269-73.
doi:10.1186/2049-3002-2-S1-O24
Cite this article as: Dirat et al.: Metformin targets the GTPase Rac1 to
inhibit prostate cancer cell migration. Cancer & Metabolism 2014 2(Suppl 1):
O24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1INSERM U1065, C3M, Nice, France
Full list of author information is available at the end of the article
Dirat et al. Cancer & Metabolism 2014, 2(Suppl 1):O24
http://www.cancerandmetabolism.com/content/2/S1/O24 Cancer & 
Metabolism
© 2014 Dirat et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
